Calliditas seeks full marketing authorization for drug to treat primary IgA nephropathy 28-Sep-2023 By Liza Laws Calliditas Therapeutics says it is optimistic about getting full marketing authorization for a drug to treat primary IgA nephropathy (IgAN) after submitting a request to the European Medicines Agency (EMA).